ClinicalTrials.gg
RecruitingNCT07125417Updated Aug 15, 2025

Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure

A Phase 4 interventional study of Single Antiplatelet Therapy or No Therapy (Control) and Non-Antithrombotic Therapy in Nonvalvular Atrial Fibrillation, Aspirin and Non-Antithrombotic Therapy, sponsored by OCEAN-SHD Study Group. Recruiting at 21 sites in Japan. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by OCEAN-SHD Study Group · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 84 studies in Atrial Fibrillation with a site in Japan — 7 open to participants now, 13 under way, 3 of them phase 3. Atrial Fibrillation · Japan.

Planned enrollment
28th of 55
500 · median 500
Started
2025
with 2 others
Phase 4
10 of 84
1 open now
Primary completion
2029-05
later than 11 of 12 live
Registered
81st of 84
by date

Among the 84 studies in Atrial Fibrillation with a site in Japan, this one is the 28th largest by planned enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2025, is one of 10 in phase 4, reaches primary completion later than 11 of the 12 other live ones, and was the 81st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

7 of the 84 studies in Atrial Fibrillation with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Atrial Fibrillation with a site in Japan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to verify that Non-Antithrombotic Therapy (NAPT) followed by Oral Anticoagulants (OAC) monotherapy for 45 days after Left Atrial Appendage Closure (LAAC) is non-inferior to Single Antiplatelet Therapy (SAPT) with aspirin during the period from randomization to the end of observational period (4 years at the maximum) in non-valvular atrial fibrillation subjects with high bleeding risk.

The primary endpoint is a composite endpoint consisting of all-cause mortality, myocardial infarction, stroke, systemic embolism, major bleeding, or clinically relevant non-fatal bleeding from randomization to the end of study observation (up to a maximum follow-up of 4 years).

  • Participants will be enrolled in this study until the day following the implementation of LAAC and will be randomized to the SAPT arm and NAPT arm in a 1:1 ratio.
  • Participants will be observed for 4 years from the time the first subject is enrolled in this study.
  • Participants will visit the hospital at 45 days, 1 year, and 2 years after enrollment, and will also be followed up by telephone, basically at the end of the observation period (up to a maximum follow-up of 4 years).

\<Study treatment duration> In both arms, OAC monotherapy will be initiated in the first 24 hours of enrollment and continued for 45 days (allowed window period: plus 2 weeks)..

  • SAPT arm will continue to receive 45 days of OAC monotherapy followed by low-dose aspirin (75~100 mg/day) as an antithrombotic agent required through the end of the study observation period.
  • NAPT arm do not receive antithrombotic medication after 45 days of OAC monotherapy through the end of the study observation period.
03

Conditions studied

  • Nonvalvular Atrial Fibrillation
  • Aspirin
  • Non-Antithrombotic Therapy
  • High Bleeding Risk
  • Left Atrial Appendage Closure

Browse trials for

Keywords

  • Left Atrial Appendage Closure
  • High bleeding risk
  • Non-Antithrombotic therapy
  • Aspirin
  • Nonvalvular Artial Fibrillation
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has documented non-valvular atrial fibrillation (i.e, atrial fibrillation without severe mitral stenosis or mechanical valves)
  2. Patient has CHA2DS2-VA score of 2 or greater
  3. Patient meets the guidelines for proper use of the left atrial appendage closure system including patient who has an increased risk of bleeding.
  4. Individual with nonvalvular atrial fibrillation who underwent successful LAAC (defined as no significant residual circumferential leak [>3 mm] or major morbidity by the time of procedure completion).
  5. Patient suitable for pharmacotherapy as defined in this study protocol in both NAPT and SAPT arms
  6. LAA anatomy is accommodate Boston Scientific WATCHMAN FLX Pro and LAAC procedure
  7. The patient and the investigator and/or subinvestigator agree that the patient will return for all required VISITs after LAAC procedure
  8. Patient has thoroughly understood the purpose of the study and has provided written to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Patients who are currently enrolled in other clinical trials, except when the patient is participating in a mandatory governmental registries or purely observational registries with no associated treatment.
  2. Individuals require long-term anticoagulation therapy for reasons other than atrial fibrillation (AF)-related stroke risk reduction (e.g.,thrombophilic conditions, previous pulmonary embolism, or deep venous thrombosis).
  3. Patients requiring oral antiplatelet therapy for reasons other than LAAC (e.g.,history of myocardial infarction, history of endovascular treatment, history of stroke/, significant coronary stenosis proven by myocardial ischemia, severe carotid stenosis requiring invasive treatment,hematologic disease such as antiphospholipid syndrome or if the investigator and/or subinvestigator judged the need for antiplatelet therapy).
  4. Patients who meet one or more of the following criteria

    • Patients who are for DOAC or VKA
    • Patients with a contraindication to aspirin
    • Patients diagnosed with an allergy to aspirin
  5. Those who have or are scheduled to undergo cardiac or noncardiac intervention or surgery 45 days or 60 days before or after LAAC (e.g.,cardioversion, PCI, cardiac ablation, cataract surgery, other structural heart interventions).
  6. Patients with stroke (either ischemic or hemorrhagic) or transient ischemic attack within 30 days prior to enrollment
  7. Patients with active bleeding
  8. Individuals who lack LAA or whose LAA has been surgically ligated
  9. Individuals who experienced a myocardial infarction (with or without intervention) recorded as a non-ST elevation myocardial infarction or ST elevation myocardial infarction in the 30-day period prior to enrollment
  10. Patients with previous atrial septal repair or with atrial septal defect/patent foramen ovale device
  11. Patients with mechanical valve prostheses at any site
  12. Persons with known contraindications to TEE
  13. Patients with active infection
  14. Individuals with class related IV congestive heart failure at enrollment
  15. Patients who are pregnant, breastfeeding, or wishing to become pregnant
  16. Patients with an expected of less than 2 years
  17. Patients requiring emergency surgery for any reason
  18. Patients who, at the discretion of the investigator, have other medical, social, or psychological conditions that preclude adherence to appropriate consent or the follow-up tests required by the protocol
  19. Other patients whose investigator or subinvestigator judges their participation in the study to be inappropriate
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Active comparator
    SAPT Arm (Single Antiplatelet Therapy Arm)

    Drug: Single Antiplatelet Therapy or No Therapy (Control)

  • Experimental
    NAPT Arm (Non-Antithrombotic Therapy Arm)

    Other: Non-Antithrombotic Therapy

Interventions

  • DrugSingle Antiplatelet Therapy or No Therapy (Control)

    Monotherapy with oral anticoagulants (OAC) including direct oral anticoagulants (DOAC) and vitamin K antagonist oral anticoagulants (VKA) for 45 days after left atrial appendage closure (LAAC), followed by aspirin-directed antiplatelet monotherapy (Single Antiplatelet Therapy: SAPT) through the end of the observational period.

  • OtherNon-Antithrombotic Therapy

    Monotherapy with OAC for 45 days after LAAC, followed by no antithrombotic therapy (Non-Antithrombotic Therapy: NAPT) from enrollment through the end of the observational period.

06

What researchers measure

Primary outcomes

  1. A composite endpoint consisting of all-cause mortality, myocardial infarction, stroke, systemic embolism, major bleeding, or clinically relevant non-fatal bleeding

    The definition of major bleeding or clinically significant nonfatal bleeding for the primary endpoint is BARC type 2, 3, or 5 bleeding among BARC type 1, 2, 3, 4, and 5. Surviving cases with no events shall be censored as of the date of discontinuation of study treatment or the date of last confirmation of survival. Planned enrollment term is two years, and all subjects will be obsserved until 4 years after first enrollment.

    Time frame: Through study completion, maximum of four years, with a minimum follow-up period of two years from the time of randomization.

Secondary outcomes

  1. Non-procedure-related BARC bleeding events of Type 1 or greater

    Non-procedure-related was defined as occurring after 7 days after the LAAC procedure. It will be assessed throughout the entire study period, as well as from the day following Visit 1 (occurring 46 to 60 days post-randomization) until the end of the study.

    Time frame: Through study completion, maximum of four years, with a minimum follow-up period of two years from the time of randomization.

  2. ISTH major bleeding not related to the procedure and clinically relevant non-fatal bleeding

    Not related to the procedure refers to events occurring 7 days after the LAAC procedure. It will be assessed throughout the entire study period, as well as from the day following Visit 1 (occurring 46 to 60 days post-randomization) until the end of the study.

    Time frame: Through study completion, maximum of four years, with a minimum follow-up period of two years from the time of randomization.

  3. Incidence of device-related thrombus (DRT) detected by CT and/or transesophageal echocardiography (TEE)

    Time frame: at Visit 1 (46~60days after randomization), 1 year, and 2 years after randomization

  4. Combined endpoint consisting of the occurrence of ischemic stroke and systemic embolism

    It will be assessed throughout the entire study period, as well as from the day following Visit 1 (occurring 46 to 60 days post-randomization) until the end of the study.

    Time frame: Through study completion, maximum of four years, with a minimum follow-up period of two years from the time of randomization.

07

Study locations

20 of 21 sites recruiting
  • Nagoya Heart Center
    Nagoya, Aichi-ken 461-0045, Japan
    Recruiting
    • Atsushi Sugiura · Contact+81-52-719-0810
    • Atsushi Sugiura · Principal investigator
  • Toyohashi Heart Center
    Toyohashi, Aichi-ken 441-8530, Japan
    Recruiting
    • Masanori Yamamoto · Contact+81-532-37-3377
    • Masanori Yamamoto · Principal investigator
  • New Tokyo Hospital
    Matsudo, Chiba 270-2232, Japan
    Recruiting
    • Toru Naganuma · Contact+81-47-711-8700
    • Toru Naganuma · Principal investigator
  • Kokura Kinen Hospital
    Kitakyushu, Fukuoka 802-8555, Japan
    Recruiting
    • Shinichi Shirai · Contact+81-93-511-2000
    • Shinichi Shirai · Principal investigator
  • Gifu Heart Center
    Gifu, Gifu 500-8384, Japan
    Recruiting
    • Tetsuro Shimura · Contact+81-58-277-2277
    • Tetsuro Shimura · Principal investigator
  • Medical Corporation Sapporo Heart Center Sapporo Cardio Vascular Clinic
    Sapporo, Hokkaido 007-0849, Japan
    Recruiting
    • Daisuke Hachinohe · Contact+81-11-784-7847
    • Daisuke Hachinohe · Principal investigator
  • Sapporo Higashi Tokushukai Hospital
    Sapporo, Hokkaido 065-0033, Japan
    Recruiting
    • Tomoyuki Tani · Contact+81-11-722-1110
    • Tomoyuki Tani · Principal investigator
  • Tokai University Hospital
    Isehara, Kanagawa 259-1193, Japan
    Recruiting
    • Yohei Ohno · Contact+81-463-93-1121
    • Yohei Ohno · Principal investigator
  • St.Marianna University Hospital
    Kawasaki, Kanagawa 216-8511, Japan
    Recruiting
    • Masaki Izumo · Contact+81-44-977-8111
    • Masaki Izumo · Principal investigator
  • Sendai Kousei Hospital
    Sendai, Miyagi 981-0914, Japan
    Recruiting
    • Masaki Nakashima · Contact+81-22-728-8000
    • Masaki Nakashima · Principal investigator
  • Kurashiki Central Hospital
    Kurashiki, Okayama-ken 710-8602, Japan
    Recruiting
    • Shunsuke Kubo · Contact+81-86-422-0210
    • Shunsuke Kubo · Principal investigator
  • The Sakakibara Heart Institute of Okayama
    Okayama, Okayama-ken 700-0804, Japan
    Recruiting
    • Takao Morikawa · Contact+81-86-225-7111
    • Takao Morikawa · Principal investigator
  • Kindai University Hospital
    Ōsaka-sayama, Osaka 589-8511, Japan
    Recruiting
    • Gaku Nakazawa · Contact+81-72-366-0221
    • Gaku Nakazawa · Principal investigator
  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
    Recruiting
    • Shinya Okazaki · Contact+81-3-3813-3111
    • Shinya Okazaki · Principal investigator
  • Mitsui Memorial Hospital
    Chiyoda-ku, Tokyo 101-8643, Japan
    Recruiting
    • Masahiko Asami · Contact+81-3-3862-9111
    • Masahiko Asami · Principal investigator
  • Sakakibara Heart Institute
    Fuchū, Tokyo 183-0003, Japan
    Recruiting
    • Yuki Izumi · Contact+81-42-314-3111
    • Yuki Izumi · Principal investigator
  • Teikyo University Hospital
    Itabashi-ku, Tokyo 173-8606, Japan
    Recruiting
    • Yusuke Watanabe · Contact+81-3-3964-1211
    • Yusuke Watanabe · Principal investigator
  • IMS Tokyo Katsushika General Hospital
    Katsushika-ku, Tokyo 124-0025, Japan
    Not yet recruiting
    • Hirofumi Hioki · Contact+81-3-5670-9901
    • Hirofumi Hioki · Principal investigator
  • Toho University Omori Medical Center
    Ōta-ku, Tokyo 143-8541, Japan
    Recruiting
    • Mike Saji · Contact+81-3-3762-4151
    • Mike Saji · Principal investigator
  • Keio University Hospital
    Shinjuku-ku, Tokyo 160-8582, Japan
    Recruiting
    • Kentaro Hayashida · Contact+81-3-5843-6702
    • Kentaro Hayashida · Principal investigator
  • Toyama University Hospital
    Toyama, Toyama 930-0194, Japan
    Recruiting
    • Hiroshi Ueno · Contact+81-76-434-7297
    • Hiroshi Ueno · Principal investigator
08

References and documents

Publications

  • Otsuka T, Yamamoto M, Asami M, Naganuma T, Ohno Y, Tani T, Nakazawa G, Izumo M, Saji M, Hachinohe D, Ueno H, Sugiura A, Shimura T, Okazaki S, Morikawa T, Izumi Y, Nakashima M, Kubo S, Shirai S, Watanabe Y, Hayashida K, Of The Ocean-Laac Investigators OB. No antithrombotic therapy versus single antiplatelet therapy after percutaneous left atrial appendage closure in non-valvular atrial fibrillation: rationale and design of the multicentre, randomised, non-inferiority NAPT-LAAC trial. EuroIntervention. 2026 Apr 20;22(8):e455-e462. doi: 10.4244/EIJ-D-25-01307. PubMed 42003301 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2029, 48 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 48 months is close to that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Aug 15, 2025
StartActual
May 29, 2025
Primary completionEst.
May 31, 2029
CompletionEst.
Mar 31, 2030
Last update
Aug 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07125417
Lead sponsor
OCEAN-SHD Study Group
Responsible party
Sponsor
First posted
Aug 15, 2025
Start date
May 29, 2025
Primary completion
May 31, 2029 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Aug 15, 2025

Study contacts

EPS Corporation
Contact
prj-laac-napt@eps.co.jp
+81-6-7176-5731

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion